Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure–response relations from two phase II clinical trials

Rifapentine is a highly active antituberculosis antibiotic with treatment‐shortening potential; however, exposure–response relations and the dose needed for maximal bactericidal activity have not been established. We used pharmacokinetic/pharmacodynamic data from 657 adults with pulmonary tuberculos...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Pharmacol Ther
Hlavní autoři: Savic, RM, Weiner, M, MacKenzie, WR, Engle, M, Whitworth, WC, Johnson, JL, Nsubuga, P, Nahid, P, Nguyen, NV, Peloquin, CA, Dooley, KE, Dorman, SE
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2017
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5545752/
https://ncbi.nlm.nih.gov/pubmed/28124478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.634
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky